Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

Moderna CEO Stephane Bancel said in a memo to employees that the company expects to reduce its workforce to fewer than 5,000 ...